ArticleBlood2010

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.

Ekkehard Mössner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.